Brendan P. Eckelman

Dr. Eckelman co-founded Inhibrx in April 2010 and currently serves as their Chief Scientific Officer and Executive Vice President of Corporate Strategy. From August 2015 to November 2018, he served as their Chief Operating Officer and Vice President of Biotherapeutics. From 2010 until August 2015, Dr. Eckelman served as their Vice President of Scientific Operations. He has served as a member of their board of directors since April 2018.

Dr. Eckelman is the head of their research team, overseeing several key functional areas spanning discovery to therapeutic development. In addition, he has critical responsibilities in corporate strategy and operations. Before co-founding Inhibrx, Dr. Eckelman was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation. He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute and received a Ph.D. in Molecular Pathology from the University of California, San Diego (UCSD), School of Medicine. Dr. Eckelman received his B.S. in Molecular Biology and his M.S. in Biology from UCSD.